Two Large Preoperative Doses of Erythropoietin Do Not Reduce the Systemic Inflammatory Response to Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 23, Issue 3, 2009, Pages 316-323

  Poulsen, Troels Dirch ^a   Andersen, Lars Willy ^a   Steinbrüchel, Daniel ^a   Gøtze, Jens Peter ^a   Jørgensen, Ole Steen ^b   Olsen, Niels Vidiendal ^a,b  

^a Copenhagen University Hospital ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cardiovascular surgery; coronary disease; cytokines; erythropoietin; inflammation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; ERYTHROPOIETIN; FENTANYL; GLUCOSE; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LACTIC ACID; MIDAZOLAM; PANCURONIUM; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SEVOFLURANE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; MALE; MEAN ARTERIAL PRESSURE; POSTOPERATIVE INFLAMMATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

AGED; CARDIAC SURGICAL PROCEDURES; DOUBLE-BLIND METHOD; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 67349185420     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2008.08.018     Document Type: Article

References (47)

1. Murphy G.J., and Angelini G.D. Side effects of cardiopulmonary bypass: What is the reality?. J Card Surg 19 (2004) 481-488
2. Raja S.G., and Dreyfus G.D. Modulation of systemic inflammatory response after cardiac surgery. Asian Cardiovasc Thorac Ann 13 (2005) 382-395
3. Hess Jr. P.J. Systemic inflammatory response to coronary artery bypass graft surgery. Am J Health Syst Pharm 62 (2005) S6-S9
4. Laffey J.G., Boylan J.F., and Cheng D.C. The systemic inflammatory response to cardiac surgery: Implications for the anesthesiologist. Anesthesiology 97 (2002) 215-252
5. Podgoreanu M.V., and Schwinn D.A. New paradigms in cardiovascular medicine: emerging technologies and practices: Perioperative genomics. J Am Coll Cardiol 46 (2005) 1965-1977
6. O'Dwyer M.J., Mankan A.K., Stordeur P., et al. The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock 26 (2006) 544-550
7. Goldie A.S., Fearon K.C., Ross J.A., et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 274 (1995) 172-177
8. Damas P., Canivet J.L., de Groote D., et al. Sepsis and serum cytokine concentrations. Crit Care Med 25 (1997) 405-412
9. Marshall J.C. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29 (2001) S99-S106
10. Patel G.P., Gurka D.P., and Balk R.A. New treatment strategies for severe sepsis and septic shock. Curr Opin Crit Care 9 (2003) 390-396
11. Fliser D., Bahlmann F.H., and Haller H. EPO: Renoprotection beyond anemia correction. Pediatr Nephrol 21 (2006) 1785-1789
12. Fliser D., Bahlmann F.H., deGroot K., et al. Mechanisms of disease: erythropoietin-An old hormone with a new mission?. Nat Clin Pract Cardiovasc Med 3 (2006) 563-572
13. Sharples E.J., Thiemermann C., and Yaqoob M.M. Novel applications of recombinant erythropoietin. Curr Opin Pharmacol 6 (2006) 184-189
14. Abdelrahman M., Sharples E.J., McDonald M.C., et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22 (2004) 63-69
15. Joyeux-Faure M., Godin-Ribuot D., and Ribuot C. Erythropoietin and myocardial protection: What's new?. Fundam Clin Pharmacol 19 (2005) 439-446
16. Brines M., and Cerami A. Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int 70 (2006) 246-250
17. Peterson T.E., and Katusic Z.S. EPO protecting the endothelium. Br J Pharmacol 150 (2007) 823-825
18. Chatterjee P.K. Pleiotropic renal actions of erythropoietin. Lancet 365 (2005) 1890-1892
19. Lipsic E., Schoemaker R.G., van der Meer M.P., et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 48 (2006) 2161-2167
20. Baker J.E. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 42 (2005) 233-241
21. Rasmussen B.S., Sollid J., Knudsen L., et al. The release of systemic inflammatory mediators is independent of cardiopulmonary bypass temperature. J Cardiothorac Vasc Anesth 21 (2007) 191-196
22. Tomic V., Russwurm S., Moller E., et al. Transcriptomic and proteomic patterns of systemic inflammation in on-pump and off-pump coronary artery bypass grafting. Circulation 112 (2005) 2912-2920
23. Feng Q. Beyond erythropoiesis: the anti-inflammatory effects of erythropoietin. Cardiovasc Res 71 (2006) 615-617
24. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6 (2005) 484-494
25. Villa P., Bigini P., Mennini T., et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198 (2003) 971-975
26. Villa P., van B.J., Larsen A.K., et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 27 (2007) 552-563
27. Gorio A., Madaschi L., Di S.B., et al. Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci USA 102 (2005) 16379-16384
28. Cuzzocrea S., Mazzon E., Di P.R., et al. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 52 (2005) 940-950
29. Le Mingh K., Klemm K., Abshagen K., et al. Attenuation of inflammation and apoptosis by Pre- and Posttreatment of Darbepoetin-alpha in Acute Liver Failure of Mice. Am J Pathol 170 (2007) 1954-1963
30. Rui T., Feng Q., Lei M., et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 65 (2005) 719-727
31. Liu X., Xie W., Liu P., et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78 (2006) 2255-2264
32. Li Y., Takemura G., Okada H., et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 71 (2006) 684-694
33. Genc K., Genc S., Baskin H., et al. Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res 55 (2006) 33-38
34. Bryl E., Mysliwska J., bska-Slizien A., et al. The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif Organs 22 (1998) 177-181
35. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495-505
36. Ehrenreich H., Fischer B., Norra C., et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130 (2007) 2577-2588
37. Ehrenreich H., Hinze-Selch D., Stawicki S., et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12 (2007) 206-220
38. Miskowiak K., O'Sullivan U., and Harmer C.J. Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. Biol Psychiatry 62 (2007) 1244-1250
39. Miskowiak K., O'Sullivan U., and Harmer C.J. Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci 27 (2007) 2788-2792
40. Miskowiak K., Inkster B., Selvaraj S., et al. Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. Neuropsychopharmacology 33 (2008) 611-618
41. Springborg J.B., Moller C., Gideon P., et al. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: A double-blind randomised clinical trial. Acta Neurochir (Wien) 149 (2007) 1089-1101
42. Lipsic E., van der M.P., Voors A.A., et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc Drugs Ther 20 (2006) 135-141
43. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100 (2003) 4802-4806
44. Bail D.H., Kofler M., and Ziemer G. Brain natriuretic peptide (BNP) in patients undergoing coronary artery bypass grafting. Thorac Cardiovasc Surg 52 (2004) 135-140
45. Andersen L.W., Landow L., Baek L., et al. Association between gastric intramucosal pH and splanchnic endotoxin, antibody to endotoxin, and tumor necrosis factor-alpha concentrations in patients undergoing cardiopulmonary bypass. Crit Care Med 21 (1993) 210-217
46. Fisher Jr. C.J., Agosti J.M., Opal S.M., et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334 (1996) 1697-1702
47. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104